Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2021 - 06 - 08 save search
Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
Published: 2021-06-08 (Crawled : 01:00) - biospace.com/
LYRA | $5.16 -4.27% -4.46% 230K
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -4.95%
treatment fda phase 2 positive
Global Zika Virus Market Pipeline Spotlight Report 2021: Key Takeaways, Treatments, Epidemiology, Drugs, Probability of Success, Clinical Trial Landscape
Published: 2021-06-08 (Crawled : 20:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.37%
H: 1.09%
C: 0.98%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.88%
H: 0.74%
C: 0.5%
treatment drug trial
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 3.92%
H: 1.51%
C: -3.02%
phase 3 trial milestone
Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
IQV | $228.09 0.41% 0.0% 760K
|
Health Services
|
| O: 0.36%
H: 0.71%
C: 0.33%
unique clinical trials trial collaboration
Global $69.5 Billion Clinical Trials Market to 2028: Increasing R&D Promoting Outsourcing & Adoption of New Technology in Clinical Research
Published: 2021-06-08 (Crawled : 18:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.49%
H: 0.05%
C: -0.16%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.36%
H: 0.25%
C: -0.46%
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
|
| O: 0.5%
H: 0.77%
C: -0.63%
new technology clinical trials research technology trial
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
Published: 2021-06-08 (Crawled : 16:00) - biospace.com/
JAN | $3.94 6.49% 6.09% 160K
|
Industrial Services
|
| O: 0.28%
H: 22.24%
C: 10.5%
disease phase 2 phase 2b trial
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
Published: 2021-06-08 (Crawled : 13:15) - biospace.com/
CRDF | $4.34 -0.69% -0.69% 610K
|
Health Services
|
| O: 0.9%
H: 5.47%
C: 2.93%
phase 2 onvansertib cancer trial pancreatic pancreas
Rising Industrial Demand for Silver Has the Mexican Mining Industry Buzzing
Published: 2021-06-08 (Crawled : 13:00) - prnewswire.com
HL | $5.31 0.57% 0.38% 6.3M
|
Non-Energy Minerals
|
| O: -0.44%
H: 1.71%
C: -0.77%
FSM | $4.65 3.1% -0.65% 5.3M
|
Non-Energy Minerals
|
| O: -0.58%
H: 0.74%
C: -2.35%
AG | $6.73 -0.59% 0.0% 10M
|
Non-Energy Minerals
|
| O: -0.85%
H: 1.2%
C: -1.37%
trial
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -2.08%
KNSA | $16.93 0.3% 0.3% 380K
|
Health Technology
|
| O: 0.15%
H: 4.0%
C: 3.13%
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.27%
H: 0.23%
C: -1.14%
trial biosimilar
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 0.37%
H: 2.71%
C: 1.47%
insulin phase 3 enroll
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Published: 2021-06-08 (Crawled : 12:15) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 2.29%
H: 0.12%
C: -1.12%
phase 3 trial
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.06%
H: 0.12%
C: -1.71%
phase 2 trial authorized application nivolumab
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
Published: 2021-06-08 (Crawled : 12:00) - globenewswire.com
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 3.35%
H: 0.15%
C: -6.65%
trial cell carcinoma
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Published: 2021-06-08 (Crawled : 11:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: 5.0%
H: 2.13%
C: -20.17%
phase 2 positive dermatitis topline trial atopic dermatitis phase 2b
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Published: 2021-06-08 (Crawled : 11:00) - biospace.com/
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 18.72%
H: 3.94%
C: 0.0%
presentation phase 2 biotech iot
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.